Medunik Canada is dedicated to providing Canadians suffering from rare diseases with access to orphan drugs that are not currently available in Canada. We make these treatment options available by building strategic partnerships with international companies to bring their products to the Canadian market. Through in-licensing partnerships, Medunik Canada offers turn-key operations and provides medical scientific liaisons, approval and market access processes and marketing for orphan disease treatments. Medunik Canada is part of the Duchesnay group, which consists of five pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. Medunik Canada was launched in 2009 to bring orphan drugs to Canadians with rare diseases. The founding of Medunik Canada was the culmination of 10 years of participation as a Corporate Council Member of the National Organization for Rare Disorders (NORD). Today, Medunik Canada brings orphan drugs to the Canadian market to provide Canadians with rare diseases with the life-changing and potentially life-saving treatment options they deserve.